Recently, AI pharmaceutical company British Silicon Intelligence announced that it has used artificial intelligence technology to discover a new mechanism for idiopathic pulmonary fibrosis drugs, which is a landmark event worldwide. In 2020, the FDA approved a total of 53 new drugs, 35 of which are small molecule drugs. This is the highest number of new drugs approved in history. And many of these drugs are aimed at known molecular targets, and it is extremely rare to find new molecules that can act on new targets for a wide range of indications. As the disease progresses, the patient's health gradually deteriorates and may be life-threatening. At present, the treatment methods for idiopathic pulmonary fibrosis are very limited. The current drugs are pirfenidone and nintedanib. In 2019, British Silicon Intelligence predicted a well-known fibrotic disease target molecule in just 21 days, and successfully verified the prediction in vitro and in vivo.